Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRI-0801
- Development stage
- Preclinical
- Lead developer
- GRI Bio
- Modality
- Small Molecules
01
Overview
GRI-0801 is a drug candidate being developed by GRI Bio as part of its pipeline of Natural Killer T (NKT) cell regulators. These therapies are designed to modulate the activity of NKT cells, which are crucial regulators early in the inflammatory cascade. By targeting NKT cells, GRI Bio aims to interrupt disease progression and restore immune system homeostasis in inflammatory, fibrotic, and autoimmune diseases. NKT cells are innate-like T cells that link innate and adaptive immune responses, with Type I invariant NKT (iNKT) cells playing a significant role in inflammation and fibrosis. While specific details for GRI-0801 are not explicitly provided, it is understood to be part of this NKT cell modulator platform.
Beyond the preview
Go deeper on GRI-0801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRI-0801.